A Randomised, 6-week, Multicentre, Open-label, Rater-blinded Parallel Group Study Comparing Quetiapine Extended Release Monotherapy and Augmentation With Lithium Augmentation in Patients With Treatment Resistant Depression.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 29 Aug 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Quetiapine (Primary) ; Lithium; Serotonin uptake inhibitors; Venlafaxine
Indications Major depressive disorder
Focus Registrational; Therapeutic Use
Acronyms RUBY
Sponsors AstraZeneca

Most Recent Events

26 May 2012 Company (GlaxoSmithKline) added to the associations field as reported by European Clinical Trials Database record.
21 Apr 2012 Planned number of patients changed from 600 to 620 as reported by European Clinical Trials Database.
28 Aug 2010 Results presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight